Background: Resveratrol is a natural, nonflavonoid polyphenol, exerting anti-inflammatory activity. It has been reported that resveratrol, together with carboxymethyl-β-glucan, can reduce nasal symptoms in children with allergic rhinitis (AR). In this study, the effect of resveratrol on nasal symptoms in adults with AR was investigated. Methods: We conducted a placebo-controlled, double-blinded study. One hundred and fifty-one adults (aged 18–60 years) with severe persistent AR were divided into a placebo-treated group (n = 50), a positive control budesonide-treated group (n = 50), and a resveratrol-treated group (n = 51). They were then treated with 2 sprays (100 µL/spray) in each nostril 3 times/day for 1 month. Nasal symptoms including obstruction, itching, sneezing, and rhinorrhea, and the levels of IgE, IL-4, TNF-α, and eosinophils in the blood were assessed at baseline and after treatment. Results: Adults treated with resveratrol or budesonide achieved a significant reduction in nasal symptoms compared to the placebo-treated group. The resveratrol treatment significantly decreased the IgE, IL-4, TNF-α, and eosinophil levels in the blood. In addition, the resveratrol treatment was found to improve the quality of life of adults with AR. Conclusion: Our preliminary study showed that intranasal resveratrol is capable of significantly improving nasal symptoms in adults with AR.

Keywords:
Resveratrol, Allergic rhinitis, Adult, Nasal symptoms, Eosinophils
1.
Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schunemann HJ, Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group: Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466–476.
2.
Dykewicz MS, Hamilos DL: Rhinitis and sinusitis. J Allergy Clin Immunol 2010; 125: S103–S115.
3.
Durham SR: The inflammatory nature of allergic disease. Clin Exp Allergy 1998; 28(suppl 6): 20–24.
4.
Miraglia Del Giudice M, Maiello N, Capristo C, Alterio E, Capasso M, Perrone L, Ciprandi G: Resveratrol plus carboxymethyl-β-glucan reduces nasal symptoms in children with pollen-induced allergic rhinitis. Curr Med Res Opin 2014; 30: 1931–1935.
5.
Brunton SA, Fromer LM: Treatment options for the management of perennial allergic rhinitis, with a focus on intranasal corticosteroids. South Med J 2007; 100: 701–708.
6.
Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F: Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999; 104: 301–304.
7.
Weinstein SF: Combination therapy in the treatment of allergic rhinitis. Allergy Asthma Proc 2002; 23: 1–3.
8.
Hernandez-Trujillo V: Antihistamines treatment for allergic rhinitis: different routes, different mechanisms? Allergy Asthma Proc 2009; 30: 584–588.
9.
Trangsrud AJ, Whitaker AL, Small RE: Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy 2002; 22: 1458–1467.
10.
Mainardi T, Kapoor S, Bielory L: Complementary and alternative medicine: herbs, phytochemicals and vitamins and their immunologic effects. J Allergy Clin Immunol 2009; 123: 283–294; quiz 295–286.
11.
Biesalski HK: Polyphenols and inflammation: basic interactions. Curr Opin Clin Nutr Metab Care 2007; 10: 724–728.
12.
Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farns-worth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218–220.
13.
Tiwari V, Chopra K: Resveratrol prevents alcohol-induced cognitive deficits and brain damage by blocking inflammatory signaling and cell death cascade in neonatal rat brain. J Neurochem 2011; 117: 678–690.
14.
Wang CY, Hua L, Sun J, Yao KH, Chen JT, Zhang JJ, Hu JH: MiR-211 inhibits cell proliferation and invasion of gastric cancer by down-regulating SOX4. Int J Clin Exp Pathol 2015; 8: 14013–14020.
15.
Wu JM, Hsieh TC: Resveratrol: a cardioprotective substance. Ann NY Acad Sci 2011; 1215: 16–21.
16.
Lee M, Kim S, Kwon OK, Oh SR, Lee HK, Ahn K: Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. Int Immunopharmacol 2009; 9: 418–424.
17.
Kim SW, Kim DW, Khalmuratova R, Kim JH, Jung MH, Chang DY, Shin EC, Lee HK, Shin HW, Rhee CS, Jeon SY, Min YG: Resveratrol prevents development of eosinophilic rhinosinusitis with nasal polyps in a mouse model. Allergy 2013; 68: 862–869.
18.
Bozdemir K, Sahin E, Altintoprak N, Muluk NB, Cengiz BP, Acar M, Cingi C: Is resveratrol therapeutic when used to treat allergic rhinitis in rats? Clin Invest Med 2016; 39:E63–E72.
19.
Andersson M, Lindqvist N, Svensson C, Ek L, Pipkorn U: Dry powder inhalation of bu desonide in allergic rhinitis. Clin Otolaryngol Allied Sci 1993; 18: 30–33.
20.
Ethier C, Lacy P, Davoine F: Identification of human eosinophils in whole blood by flow cytometry. Methods Mol Biol 2014; 1178: 81–92.
21.
Platts-Mills TA: The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001; 164:S1–S5.
22.
Ohashi Y, Nakai Y, Okamoto H, Ohno Y, Sakamoto H, Sugiura Y, Kakinoki Y, Tanaka A, Kishimoto K, Washio Y, Hayashi M: Serum level of interleukin-4 in patients with perennial allergic rhinitis during allergen-specific immunotherapy. Scand J Immunol 1996; 43: 680–686.
23.
Iwasaki M, Saito K, Takemura M, Sekikawa K, Fujii H, Yamada Y, Wada H, Mizuta K, Seishima M, Ito Y: TNF-α contributes to the development of allergic rhinitis in mice. J Allergy Clin Immunol 2003; 112: 134–140.
24.
Sood A: Diagnostic significance of nasal eosinophilia in allergic rhinitis. Indian J Otolaryngol Head Neck Surg 2005; 57: 13–16.
25.
Naclerio RM: Allergic rhinitis. N Engl J Med 1991; 325: 860–869.
26.
Pawankar R, Yamagishi S, Yagi T: Revisiting the roles of mast cells in allergic rhinitis and its relation to local IgE synthesis. Am J Rhinol 2000; 14: 309–317.
27.
Pawankar R, Mori S, Ozu C, Kimura S: Overview on the pathomechanisms of allergic rhinitis. Asia Pac Allergy 2011; 1: 157–167.
28.
Naclerio RM, Proud D, Togias AG, Adkinson NF Jr, Meyers DA, Kagey-Sobotka A, Plaut M, Norman PS, Lichtenstein LM: Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985; 313: 65–70.
29.
Han SY, Bae JY, Park SH, Kim YH, Park JH, Kang YH: Resveratrol inhibits IgE-mediated basophilic mast cell degranulation and passive cutaneous anaphylaxis in mice. J Nutr 2013; 143: 632–639.
30.
White M: Mediators of inflammation and the inflammatory process. J Allergy Clin Immunol 1999; 103:S378–S381.
31.
Bisgaard H, Olsson P, Bende M: Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986; 16: 289–297.
32.
Silva AM, Oliveira MI, Sette L, Almeida CR, Oliveira MJ, Barbosa MA, Santos SG: Res-veratrol as a natural anti-tumor necrosis factor-α molecule: implications to dendritic cells and their crosstalk with mesenchymal stromal cells. PLoS One 2014; 9:e91406.
33.
Tan Y, Lim LH: Trans-resveratrol, an extract of red wine, inhibits human eosinophil activation and degranulation. Br J Pharmacol 2008; 155: 995–1004.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.